Another study found that impaired activity of Nrf2/ARE signaling pathway was a driver mechanism in Hutchinson-Gilford progeria syndrome through high-throughput RNAi screening, and Oltipraz, a Nrf2-activating agents, could ameliorate the progeroid phenotype [42]. The gene discussed is NFE2L2; the disease is Hutchinson-Gilford progeria syndrome.